992 related articles for article (PubMed ID: 26377368)
21. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.
Young JL; Sarkis E; Qiao M; Wietecha L
Clin Neuropharmacol; 2011; 34(2):51-60. PubMed ID: 21406998
[TBL] [Abstract][Full Text] [Related]
22. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.
Adler L; Tanaka Y; Williams D; Trzepacz PT; Goto T; Allen AJ; Escobar R; Upadhyaya HP
J Clin Psychopharmacol; 2014 Aug; 34(4):461-6. PubMed ID: 24977716
[TBL] [Abstract][Full Text] [Related]
23. Default mode network activity and neuropsychological profile in male children and adolescents with attention deficit hyperactivity disorder and conduct disorder.
Uytun MC; Karakaya E; Oztop DB; Gengec S; Gumus K; Ozmen S; Doğanay S; Icer S; Demirci E; Ozsoy SD
Brain Imaging Behav; 2017 Dec; 11(6):1561-1570. PubMed ID: 27738997
[TBL] [Abstract][Full Text] [Related]
24. Modifications in resting state functional anticorrelation between default mode network and dorsal attention network: comparison among young adults, healthy elders and mild cognitive impairment patients.
Esposito R; Cieri F; Chiacchiaretta P; Cera N; Lauriola M; Di Giannantonio M; Tartaro A; Ferretti A
Brain Imaging Behav; 2018 Feb; 12(1):127-141. PubMed ID: 28176262
[TBL] [Abstract][Full Text] [Related]
25. The effect of single-dose methylphenidate on resting-state network functional connectivity in ADHD.
Silk TJ; Malpas C; Vance A; Bellgrove MA
Brain Imaging Behav; 2017 Oct; 11(5):1422-1431. PubMed ID: 27734305
[TBL] [Abstract][Full Text] [Related]
26. A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.
Tsang TW; Kohn MR; Hermens DF; Clarke SD; Clark CR; Efron D; Cranswick N; Lamb C; Williams LM
Trials; 2011 Mar; 12():77. PubMed ID: 21396130
[TBL] [Abstract][Full Text] [Related]
27. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
[TBL] [Abstract][Full Text] [Related]
29. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
[TBL] [Abstract][Full Text] [Related]
30. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
31. Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.
Thome J; Dittmann RW; Greenhill LL; Lipsius S; Tanaka Y; Bushe C; Escobar R; Heinloth AN; Upadhyaya H
Atten Defic Hyperact Disord; 2017 Dec; 9(4):219-229. PubMed ID: 28477289
[TBL] [Abstract][Full Text] [Related]
32. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
33. Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.
Cubillo A; Smith AB; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
Psychol Med; 2014 Feb; 44(3):633-46. PubMed ID: 23597077
[TBL] [Abstract][Full Text] [Related]
34. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
[TBL] [Abstract][Full Text] [Related]
35. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
36. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
37. Disrupted network architecture of the resting brain in attention-deficit/hyperactivity disorder.
Sripada C; Kessler D; Fang Y; Welsh RC; Prem Kumar K; Angstadt M
Hum Brain Mapp; 2014 Sep; 35(9):4693-705. PubMed ID: 24668728
[TBL] [Abstract][Full Text] [Related]
38. Single-dose effects of methylphenidate and atomoxetine on functional connectivity during an n-back task in boys with ADHD.
Kowalczyk OS; Cubillo AI; Criaud M; Giampietro V; O'Daly OG; Mehta MA; Rubia K
Psychopharmacology (Berl); 2023 Oct; 240(10):2045-2060. PubMed ID: 37500785
[TBL] [Abstract][Full Text] [Related]
39. Assessment of effects of atomoxetine in adult patients with ADHD: consistency among three geographic regions in a response maintenance study.
Tanaka Y; Escobar R; Upadhyaya HP
Atten Defic Hyperact Disord; 2017 Jun; 9(2):113-120. PubMed ID: 28058589
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
Buitelaar JK; Michelson D; Danckaerts M; Gillberg C; Spencer TJ; Zuddas A; Faries DE; Zhang S; Biederman J
Biol Psychiatry; 2007 Mar; 61(5):694-9. PubMed ID: 16893523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
